Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy

Abstract Fabry disease (FD) is a rare X‐linked disorder of lipid metabolism, characterized by the accumulation of globotriaosylceramide (Gb3) due to defective the lysosomal enzyme, α‐galactosidase. Gb3 deposits activate immune‐mediated systemic inflammation, ultimately leading to life‐threatening co...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Li Fu, Sylwia Wasiak, Laura M. Tsujikawa, Brooke D. Rakai, Stephanie C. Stotz, Norman C. W. Wong, Jan O. Johansson, Michael Sweeney, Connie M. Mohan, Aneal Khan, Ewelina Kulikowski
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2022-06-01
coleção:	Pharmacology Research & Perspectives
Assuntos:	apabetalone BETi epigenetics Fabry disease inflammation oxidative stress
Acesso em linha:	https://doi.org/10.1002/prp2.949
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!